Division/Committee: [MEDI: Division of Medicinal Chemistry]

Obesity presents a significant global public health challenge, with implications ranging from type 2 diabetes to cardiovascular disease. Among the current therapeutic options, traditional peptide agonists targeting the glucagon-like peptide-1 receptor (GLP1R) have shown effectiveness in treating obesity and diabetes. However, limitations such as high cost and the requirement for subcutaneous injections have hindered their widespread adoption. To address these limitations, ongoing research endeavors are focusing on the development of oral small molecules and exploring alternative targets beyond GLP1R. These advancements aim to overcome drawbacks associated with peptide-based therapies, reduce treatment costs and facilitate convenient oral administration. This symposium will showcase the latest breakthroughs in obesity treatment, with a specific emphasis on the development of non-peptidic therapeutics and emerging targets, such as GLP-1R, GIPR, CB1R, and MGAT2, for obesity treatment. By highlighting these advancements, the symposium seeks to address the demand for innovative strategies in combating obesity. With the weight management market witnessing significant growth and numerous promising clinical assets under development, the symposium is expected to attract a diverse audience interested in exploring cutting-edge approaches to tackle the global obesity epidemic.

Christopher McAtee

Janssen Global Services LLC

Appearances